Transcend CLL 004: Minimal Residual Disease After Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.71_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Outcomes With Bruton Tyrosine Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Progression on Venetoclax

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

The PI3Kδ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Safety and Efficacy of Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

Frontiers in Oncology
Cancer ResearchOncology
2019English

Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Cytometry Part B - Clinical Cytometry
Forensic MedicinePathologyHistologyCell Biology
2017English

Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (Cll) Relapsed or Refractory in Argentina

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Impacts of Zanubrutinib on Immune Cells in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy